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 ABSTRACT 
Autoantibody-positive rheumatoid arthritis (RA), also called seropositive RA, is characterised 
by the presence of anti citrullinated proteins antibodies (ACPA) that can be detected in blood 
several years before disease onset. Joint inflammation, pain and bone destruction are major 
features of the disease. Classically bone destruction and pain have been considered to be late 
events in the disease development, resulting from long lasting and uncontrolled 
inflammation. However, both bone loss and pain have been reported in both seropositive 
individuals not yet having the disease and those seropositive individuals just being diagnosed 
with seropositive RA. Taken together these findings suggest that other factors than 
uncontrolled joint inflammation might drive the process of bone loss and pain in RA. We 
hypothesized that antibodies themselves and specifically ACPA might play a direct role in 
mediating bone loss and pain and aimed to investigate the role of ACPAs in bone metabolism 
and pain-like behaviour in mice.  
To investigate bone metabolism, we focused on studies of osteoclasts (OC), cells responsible 
for bone loss in vitro (by assessing formation and maturation of OC in cell cultures and 
estimating their capacity to degrade bone matrix in vitro) and in vivo (by micro-CT analysis 
of the bone density). We have demonstrated that polyclonal and monoclonal ACPAs isolated 
from the blood and synovial fluid of RA patients enhance the number of OC and of their bone 
resorptive capacity in vitro. This effect was accompanied by a significant increase of IL-8 
levels in OC supernatants and abolished by neutralizing anti IL-8 antibodies. Further, ACPA 
injected in mice were shown to bind to CD68-positive OC precursors in bone marrow in the 
vicinity of the joints and to promote trabecular bone loss, which was also reversed by 
blocking the mice homologues of IL-8, CXCL1/2 by using reparixin. In parallel to bone 
destruction ACPA also induced pain-like behaviour in mice, that similar to bone loss was 
also abolished by CXCL1/2 blocking. Taken together these findings suggest that ACPA 
promote bone loss by inducing IL-8 that in turn can further amplify the bone loss process and 
induce pain-behaviour. 
As ACPA, but no other immunoglobulins (non-ACPA immunoglobulins from RA patients, 
non-ACPA Ig from healthy individuals) were able to promote bone loss, we investigated the 
role of citrullination in ACPA-mediated osteoclastogenesis. We demonstrated that 
citrullination by peptidyl arginine deiminases (PAD) enzymes is essential for the 
physiological development and maturation of OCs but no other cells (such as synovial 
fibroblasts). This finding might explain the ACPA preference for OCs. Further we showed 
that ACPA bind to targets expressed on the surface of OCs. Blocking the citrullination 
  
machinery by PAD enzyme inhibitors significantly abrogates ACPA binding to OCs and 
ACPA-mediated osteoclastogenesis.  
OCs could develop from different cell precursors and inflammatory conditions, such as joint 
inflammation in RA, promote the transdifferentitation of immature DC (iDC) into OCs. In 
order to investigate if ACPA might also play a role in this proces, we analyzed the capacity of 
polyclonal and monoclonal ACPA to promote the in vitro transdifferentation of iDC to OC. 
We showed that despite a clearly distinct protein profile as compared to classical macrophage 
OC precursors, iDC are able to develop into remarkably similar OCs. Plasticity towards OC 
differentiation correlated with PAD activity and protein citrullination expression levels in 
iDC cultures. Citrullinated actin and vimentin were present in iDCs and iDC-derived OCs 
and both proteins were deposited on the cell surface, co-localising with ACPAs binding to the 
cells. ACPAs enhanced OC differentiation from both monocyte-derived iDCs and from 
circulating CD1c+ DCs. Blocking either PAD activity or ACPA-induced IL-8 secretion 
completely abolished the stimulatory effects of citrulline-targeting antibodies on DC-OC 
transdifferentiation. We further explored the mechanisms involved in the plasticity of iDC 
and their capacity to develop into OCs showing that cell culture densities and lactate 
concentrations are essential mediators. DCs originating from dense cultures developed in the 
presence of high lactic acid doses, have high PAD activity and increased efficiency to convert 
into OC and erode bone. In contrast, DCs from sparse cultures have low PAD activity with 
decreased OC potential.  
In conclusion, the current thesis describes novel mechanisms by which RA-associated 
antibodies target OC to induce bone loss and pain. Our studies provide insights into the 
mechanisms by which systemic autoimmunity might target the joints and suggest potential 
novel ways to prevent this. 
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1 INTRODUCTION 
1.1 Rheumatoid arthritis 
1.1.1 Definition and clinical picture  
Rheumatoid arthritis (RA) is a  chronic inflammatory autoimmune disease characterized by 
joint destruction and pain that might lead to longstanding physical disability affecting the 
quality of life in the absence of appropriate treatments (1, 2). RA has an annual incidence of 
0.2% in males and 0.4% in females with a prevalence of around approximately 1% in the 
world population (1, 3). Pain and swelling of the small finger joints (metacarpophalangeal 
(MCP) and proximal interphalangeal (PIP) joints), in wrists and forefeet, mainly the 
metatarsophalangeal joints (MTP) are most common symptoms (4). If left untreated the 
disease leads to destruction of cartilage and bone. The clinical picture of the disease varies 
between individuals, with some presenting a more aggressive bone and cartilage destruction, 
while others have no erosion (5). The treatment today consist in often long life use of disease-
modifying anti-rheumatic drugs (DMARDs), both synthetic DMARDs and biological 
DMARDs, a collection of heterogeneous treatment agents that reduces the joint swelling and 
pain and also limits the joint damage (6). 
1.1.2 Criteria for RA 
The 1987 American college of Rheumatology (ACR) classification criteria for RA are: 
morning stiffness, arthritis of 3 or more joint areas, arthritis of hand joints, symmetric 
arthritis, rheumatoid nodules, positive serum rheumatoid factor(RF), and radiographic 
changes.  Definite RA is diagnosed if more than 4 of these 7 criteria are fulfilled (7). In 2010 
ACR/EULAR criteria was framed to diagnose RA in early stages of the disease, the new 
criteria aims to prevent the structural damage by initiating therapy in earlier stage (8).  The 
new criteria focus on the joint involvement (number and sites involved in the joint), serologic 
abnormality (RF and ACPA), acute-phase reactants and symptom duration (8). Presence of 
the autoantibodies against the citrullinated antigen (ACPAs) and the autoantibodies against 
the Fc part of self-IgGs known as rheumatoid factor (RF) can be used to sub-divide RA 
patients. Based on the autoantibody positivity the patients can be classified as seropositive 
and seronegative RA,  which differ from one another in terms of their respective disease 
courses (9). 
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1.1.3 History of serological markers in the clinical diagnosis of RA 
RF was initially identified as an antibody against serum gamma-globulin in 1940 (10). Later, 
it was found that these antibodies are detectable in other infectious and autoimmune diseases 
(11).  In 1948 RF was described in patients with RA (11) and from 1987, it has been included 
in the clinical diagnosis of RA (12). 
In the early 1960, it was found that the antibodies present in the RA-sera reacted specifically 
to keratohyalin granules and later this property was employed in the serological test popularly 
known as anti-perinuclear-factor (APF) test. (13) After several years of research the antigen 
was found to be modified filaggrin present in the fully differentiated epithelial cells where the 
aminoacid  arginine  was replaced by citrulline (14). These findings were later confirmed by 
the high specificity binding of the RA-associated autoantibodies to the citrullinated filaggrin 
or linear citrullintaed peptides but the sensitivity was low (15). Later, citrullinated peptides 
were changed to cyclic citrullinated peptides (CCP), resulting in an improved sensitivity of 
68% and specificity of 98% (16). It was followed by the development of CCP2 test and is 
being used as standard ELISA in the clinics for ACPA detection (17).  
1.2 Etiopathogenesis of the longitudinal development of seropositive RA 
Current understanding of the seropositive RA pathogenesis, suggests that the development of 
RA-associated autoantibodies in individuals with specific genetic background leads first to 
unspecific symptoms (such as pain and fatigue) that later culminate in chronic joint 
inflammation, in some but not all of these individuals. This section discusses the current state 
of the art regarding the longitudinal development of seropositive RA (5) which is 
schematically represented in figure 1.  
1.2.1 Genes 
Genetical background can be an important risk factor for the development of RA and it can 
also influence disease severity. Epidemiological studies has shown an association between 
human leukocyte antigen (HLA)-DRB1 alleles and RA (18, 19). Shared epitope (SE) consists 
of five aminoacids from the position 70-74 in DRß chain is encoded by the HLA-DRB1 gene 
and involved in the antigen presentation by T cells (19). SE is associated with the increased 
diseases severity and erosions (19, 20). Furthermore, the presence of SE is linked to the 
predisposition towards ACPA positive RA (21) and this contribution is only linked to the 
ACPA development but not to the diseases progression (22). Studies on the non-MHC 
associated genes have also been reported to associate with RA. Risk alleles are Protein 
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tyrosine phosphatase non-receptor 22 (PTPN22) (23) is associated in both seropositive and 
seronegative RA patients (24),  whereas Cytotoxic T-lymphocyte protein 4 (CTLA-4) (25) 
and peptidyl-arginine deiminase type 4 (PADI4) (26) are associated with  only seropositive 
RA patients.  
1.2.2 Environmental factors 
RA is characterized by complex gene–environment interactions (27). Long-term smoking, 
particularly in individuals carrying SE in the MHC molecules, is strongly associated with the 
risk of developing seropositive RA (28) (29). Other factors like silica and textile dust 
exposure are also associated with the ACPA-positive RA development (30, 31).  
In a case control study involving subjects exposed to silica and rock drilling have 1.5fold and 
2.5fold increased risk of developing ACPA positive RA (31).  Exposure to silica with current 
smoking additively increased the risk of the developing RA (31, 32).In a Malaysian-based 
case control study, textile dust exposed females have an increased risk of developing ACPA 
positive RA by an odds ratio(OR) of 2.8 (33). OR was even higher in those individuals that 
have both the shared epitope  and textile dust exposure (33). A U.S and Swedish cohort study 
based on the exposure to air pollutants such as particulate matter (PM10 and PM2.5) and 
gaseous pollutants (SO2 and NO2) showed no association to the risk of developing RA (34). 
On the contrary, a study on exposure to the traffic pollution suggests that the woman living as 
close 50m to the major roads have increased risk of developing RA compared to those living 
farther (35).These findings have led to the hypothesis that mucosal surface in the lungs might 
be involved in triggering RA development. 
1.2.3 Environmental challenges lead to mucosal immune activation  
Environmental challenges (such as smoking) directly affect the mucosal surfaces of the body. 
These mucosal surfaces are trying to maintain an equilibrium between external challenges 
(either negative of positive) and the body homeostasis, through innate and adaptive immune 
mechanisms (36). A recent study in the ACPA positive patients with early untreated RA 
demonstrated presence of lung abnormalities on high resolution computed tomography 
(HRCT) (37). This was associated with signs of immune activation, increased expression of 
citrullinated proteins and ACPA enrichment (38). ACPAs are also enriched in the sputum of 
the individuals at-risk of developing RA and correlate with other inflammatory parameters 
detected in the sputum (39, 40). These observations give support for an initial immune attack 
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leading to tolerance breaching and immune activation at extra-articular sites, particularly at 
mucosal sites. 
1.2.4 Systemic autoimmunity prior to disease onset 
Following their appearance at mucosal sites, ACPAs can be present in the circulation several 
years, together with RF antibodies, before the onset of systemic inflammation (41). The 
presence of these autoantibodies is associated with an increased risk of developing RA, and 
the constantly evolving ACPA fine specificities lead to epitope spreading and a broad range 
of recognized targets by the onset of RA (41, 42). As discussed later in the thesis, increase in 
ACPA production and diversification of the recognized targets typically accompanies the 
initiation of RA suggesting a potential role for ACPAs in the progression towards the disease 
although the cause and consequence relationship between the increase of ACPA responses 
and systemic inflammation is yet to be fully understood  (43, 44). Moreover, ACPAs against 
different target molecules can increase or remain at low level during RA onset suggesting that 
certain ACPA specificities might be more important for disease progression than others (45). 
In addition, different ACPA isotypes can be present in the circulation with IgG ACPAs being 
the most predictive for disease onset and the number of detectable ACPA isotypes (IgG1, 
IgG2, IgG3, IgG4, IgA or IgM) by the initiation of RA has been shown to correlate with 
radiographic damage in the course of the disease (40, 46). Recent analysis of a potential 
hierarchy within ACPA responses against exogenous or endogenous antigens being more 
relevant for progression towards RA has not detected any such difference (47). 
It is important to note that although the presence of ACPAs alone is not sufficient for RA 
development, together with genetic risk factors (such as HLA SE), environmental risk factors 
(such as smoking) and the presence of joint pain, ACPA positivity indicates a high chance for 
eventual progression towards RA. 
1.2.5 Chronic joint inflammation 
Yet unknown mechanisms are responsible for the transition between systemic autoimmunity 
and joint inflammation and these mechanisms still remain to be identified. Once joint 
inflammations can be detected in form of swollen and painful joints in a seropositive 
individual, a diagnosis of RA can be made in a large majority of the cases. This phase is 
characterized by development of chronic synovitis with increased infiltration of mononuclear 
cells and lymphocytes is reported into the synovial tissue and synovial fluid (SF) of the RA 
patients (5) as well as the activation and expansion of macrophages (MФ) and fibroblast-like 
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cells that compose the synovial membrane (48). The activated stroma and the infiltrating 
immune cells release an array of inflammatory mediators that increase immune activation, 
chemotaxis, osteoclast (OC) development and angiogenesis in the newly expanded synovial 
tissue. ACPAs and RF antibodies can further accelerate immune activation through triggering 
cytokine production in MФ and dendritic cells (DCs) through immune complex-mediated 
triggering of activating FcRs on these cells (49). The chronic inflammation fuels cartilage and 
bone destruction due to the increase of OC differentiation and through the invasion of 
cartilage by erosive synovial fibroblasts (50, 51) (52)  
Figure 1: Longitudinal view of the seropositive rheumatoid arthritis 
Genetic and environmental factors have vital role in the development of RA. Genetically 
susceptible individuals challenged with environmental factors as smoking, textile dust and 
microorganisms could trigger the local inflammation and immune activation that results in 
the loss of tolerance against the self-proteins and leads to the autoantibody generation by the 
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adaptive immunity. Autoantibodies increase in the titre and undergo epitope spreading. Over 
time, these autoantibodies gradually increase in titre and epitope spreading happens which 
occurs before the onset of the disease. Studies have linked the autoantibody positivity to bone 
loss and pain. During this period, a minor challenge or infection could lead to chronic 
inflammation and arthritis development. 
1.3 Tolerance breaking and immune activation in RA 
As mentioned above tolerance braking in RA could be initiated at mucosal sites and 
posttranslational modifications induced by exposure to air pollutants such as smoking are 
believed to play an essential role.  
1.3.1 Role of post-translational modifications  
Post-translational modifications (PTMs) lead to covalently modified proteins often with 
altered biochemical properties that can affect protein-protein interactions or enzymatic 
reactions (53). There are around 200 different types of PTMs identified (54), out of these 
citrullination, carbymylation, acetylation and malondihyde modification have been studied in 
RA (55) due to detectable autoantibody responses against the modified proteins in RA (55). 
As autoimmunity against citrullinated modified proteins is one of the most frequent detected 
and specific autoimmunity in patients with RA, we have in the current thesis focused on 
investigation of citrullination as a prototype PTM.  
1.3.1.1 Citrullination 
Citrullination is the conversion of peptidyl arginine to peptidyl citrulline and was first defined 
by Rogers and Simmonds in 1958 (56). This modificaiton renders the strong positive charge 
in arginine into neutral citrulline (57).  The change in the charge of the proteins leads to 
decrease in the mass of the citrullinated protein by 1Da (57). Citrullinated  proteins are 
present in the cytoplasm, nucleus, plasma membrane and mitochondria of a cells (58). 
Citrullination can occur in various tissues under both physiological and pathological 
circumstances (59).   
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Figure 2: Process involved in Citrullnation 
This figure shows the hydrolytic reaction by PAD enzymes that converts the peptidyl 
arginine into peptidyl citrulline in presence calcium.  The conversion results in the change in 
the charge from positive to neutral. 
During late differentiation phases of keratinocytes, citrullination of their main intermediate 
filament protein, the cytokeratin, enables structural changes that alters the spectrum of 
cytoskeleton-linked membrane proteins (57, 60). During the development of the brain, in the 
first two years of life an elevated citrulination of myelin basic protein allows increased 
neuronal plasticity, which is followed later by drastically reduced citrullination of the same 
protein (60). Histone citrullination regulates the chromatin structure, and it is required for the 
pluripotency of stem cells (61). Vimentin is another important intermediate filament protein 
that is present in various cell types and plays important roles in adhesion and cell migration 
(62). During apoptosis, citrullination of vimentin reduces the isoelectric point of the head 
domain, decreasing the capacity of the protein to polymerise, which potentially contributes to 
the morphological changes occurring in apoptotic cells (57). Citrullination alters the 
immunological functions of the chemokine IL-8(CXCL8), through interfering with the 
maturation of this chemokine by thrombin-mediated proteolysis and thereby decreasing the 
neutrophil recruiting capacity of the molecule (59).  
Increased protein citrullination has been associated with autoimmune diseases, inflammation 
or trauma. In multiple sclerosis patients increased citrullination of histones is reported in the 
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normal white matter and in animal models demyelination. In the same report TNF was 
identified as the mediator that induced citrullination by inducing PAD4  (63). In RA, 
citrullinated protein have been identified in the joints, including several known target for 
ACPAs (e.g. vimentin, enolase, fibrinogen). Smoking has been associated with increased 
citrullination, which is likely to contribute to an increased risk for developing ACPA-positive 
RA. Traumatic brain injury leads to increased citrullination in certain regions in the brain, 
occurring mostly in astrocytes (64). 
1.3.1.1.1 PAD enzymes  
Peptidyl arginine deiminases (PAD) are enzymes responsible for citrullination. PAD enzymes 
were identified in 1977, they can citrullinate arginine in the proteins but cannot citrullinate 
methylated arginine in the context of the protein (65). In humans there  are five PAD 
isozymes, they are PAD1, PAD2, PAD3, PAD4 and PAD6, all the PAD isozymes except 
PAD6 has in-vitro activity. PAD2 and PAD4 are distributed in wide range of tissues and cells 
has been implicated in several diseases like RA, cancer, ulcerative colitis, Alzheimers 
diseases and multiple sclerosis (58).  
Early studies on the catalytic activity of PADs has demonstrated that high amount of calcium 
(5-10mM) is required for the PAD enzymes to get activated in vitro (66, 67).  This extremely 
high concentration is difficult to achieve in the normal physiology. Recently, anti-PAD4 
(identified by cross-reactivity with PAD3) autoantibodies has been described, these 
antibodies can increase the catalytic efficiency of PAD4 decreasing the requirement of the 
calcium to the physiologic range. PAD activity and expression has been detected in the SF 
and peripheral blood monocytes and macrophages (68) of RA patients (69). In relation to the 
PAD activity SF calcium levels were reported to be sufficient to citrullination of the proteins 
(69). Interestingly, monocytes can upregulate PAD2 and PAD4 expression when they interact 
with the activated T-cells, providing a source for increasing levels of PAD enzymes (70). It 
has been recently shown that the TNF can interact with PAD4 to increase the citrullination 
thereby increase the autoantibody production against native and citrullinated targets. 
Moreover, TNF transgenic mice lacking PAD4 showed decreased autoantibody production 
and inflammatory arthritis (71). Expression of the PAD enzymes and citrullinated proteins are 
increased in the inflamed tissue sites in the patients with autoimmune diseases and colitis 
(72). Citrullinated vimentin stimulated the proliferation  of the fibroblasts from RA patients, 
in addition stimulating proinflammatory cytokine secretion (73). The relation between PAD 
overexpression and inflammation has been implicated but the mechanism behind the 
increased inflammation with increase in PAD has not been described until recently. A report 
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on PAD4  in neutrophils suggests that PAD4 can citrullinate NF-kB p65 thereby enhancing 
their nuclear localization and inducing the  inflammatory cytokines (74). These findings 
suggests that PAD mediates inflammation through their capacity to regulate transcription 
factors and through other unknown mechanisms . 
As abnormal PAD activity has been implicated in several diseases state, PAD blocking agents 
have been suggested as potential therapeutic agents in several animal models including RA 
(75-78). Recently, it has been shown that targeting PAD enzymes increased apoptosis of the 
inflammatory cells in the colitis mice model, suppressing the colitis (75).  In malignant 
tumours, PAD enzymes are overexpressed downregulating the tumour suppressor p53 
expression, inhibiting PAD enzymes in xenograft tumour model proved to be effective in 
suppressing the tumour growth by activating the tumour suppressor gene expression (79).  In 
experimental autoimmune encephalomyelitis (EAE),  an animal model for CNS 
demyelinating disease, hypercitrullination by PADs correlates with the diseases activity, 
blocking the PAD enzymes before the initiation of the autoimmunity prevented the disease by 
suppressing the autoreactive T cells (80). Interestingly, Cl-amidine a PAD inhibitor treatment 
of murine collagen induced arthritis (CIA) model lead to decrease in  synovial and serum 
citrullination, followed by decrease in disease activity by 50 %  and  reduced IgG2a anti-
mouse collagen antibodies (81).  
1.3.2 Role of Innate immunity  
The innate immune system is composed of several soluble and cellular components, which 
are rapidly activated in response to danger signals that indicate tissue damage or the presence 
of invading pathogens (82). Activation of the innate mechanisms provides a first line defence 
for the host organism and it also sets the stage for the adaptive arm of the immune system 
through and array of inflammatory/co-stimulatory mediators that facilitate T cell and B cell 
responses (36). Innate immune mechanisms are crucial for the initiation of autoimmune 
responses as well, with triggering mechanisms potentially including endogenous compounds, 
environmental stimuli or microbial factors (83, 84). Smoking and other environmental insults 
of the airway mucosa are well-known risk factors for seropositive RA and these signals might 
broadly influence the airway epithelial and antigen presenting cells by causing oxidative 
stress or through compounds that directly regulate these cells (83, 85). Interestingly, cigarette 
smoke induces approximately 100X increase in airway endotoxin exposure as compared to 
smoke-free environment (86, 87). The activation of pattern-recognizing receptors, such as 
Toll-like receptors or inflammasome components, in response to cigarette smoke can result in 
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the production of inflammatory cytokines and chemoattractants by cells in the airways (36). 
Moreover, MФs and DCs have been shown to respond with altered phenotype and 
functionality to cigarette smoke, with both inhibitory and stimulatory effects described (88, 
89)(78). These cells might play a particularly important role in the initiation of the anti-
citrullinated protein responses due to persistent steady state citrullination occurring in their 
autophagic compartments and a subsequent MHC-II dependent presentation of citrullinated 
peptides on the cell surface (90). In addition to a potential activation of antigen presenting 
cells in the airways, cigarette smoke could further contribute to the initiation of citrullinated 
protein-specific immune responses through increasing PAD enzyme expression and the 
amount of citrullinated proteins in the lungs (89). 
Neutrophil granulocytes constitute a crucial first-line defence against extracellular pathogens 
due to their phagocytic and intracellular killing activities and release of neutrophil 
extracellular traps (NETs), a network of externalised chromatin, which can immobilise and 
kill several pathogens (91). NET production requires PAD4 activity and histone 
hypercitrullination, suggesting that NETosis might play an important role in providing 
citrullinated proteins to the adaptive immune system (92).  In addition, the periodontal 
pathogen Aggregatibacter actinomycetemcomitans (Aa) has been shown to induce 
hypercitrullination in neutrophils, likely through the pore-forming toxin leukotoxin A, which 
activates PAD enzymes by inducing Ca2+ influx in the cells and also facilitates a subsequent 
netosis (93). Interestingly, the association of HLA SE expression and RA-associated 
autoantibodies was restricted to Aa-positive patients in this study, suggesting the importance 
of this neutrophil-bacterium interaction in the initiation of seropositive RA. 
Innate immune cells play important roles in established RA as well, through contributing to 
the production of inflammatory mediators and the presentation of autoantigens to the adaptive 
immune system. Monocytes, MФs and DCs are recruited to the inflamed joints and can 
differentiate into OCs contributing to bone damage . Immune mediators turn fibroblasts of the 
synovial membrane into an expanding inflammatory stroma that erode cartilage, present 
antigens to the infiltrating T lymphocytes and release an array of cytokines, matrix degrading 
enzymes, chemoattractant, angiogenic or osteoclastogenic compounds (94). Therapies 
targeting key inflammatory cytokines are among the most efficient approaches tested so far to 
ameliorate RA, indicating the profound importance of these pathways in disease pathogenesis 
(95) . 
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1.3.3 Role of adaptive immunity   
Genes encoding HLA-SE or PTPN22, a phosphatase that regulates T and B cell receptor 
signaling, are the most prominent susceptibility loci that have been associated with ACPA-
positive RA indicating a prominent role for adaptive immunity in RA (9). Protein 
citrullination, due to converting a positively charged arginine to a neutral citrulline, has been 
shown to increase binding affinity of several antigenic peptides to the positively charged P4 
pocket in HLA-DRB1 molecules, proposing a model where a preferential presentation of 
citrullinated autoantigens could trigger autoreactive T cells responses in SE-positive 
individuals (9). Additionally, citrullination affects proteolysis and consequently alters the 
repertoire of the presented peptides (96). Moreover, in some cases, citrullination of the 
enolase protein was likely to affect interaction with the TCR of autoreactive T cells instead of 
MHC binding (97). T cell reactivity to citrullinated autoantigens facilitate B cell responses 
and the subsequent ACPA production. ACPAs have been detected in the airways as well as in 
the serum of individuals at risk for developing RA and the work presented in this thesis 
focused largely on the role of these antibodies in the initiation of RA due to mechanisms 
contributing to bone erosion and pain. A rapid increase in epitope spreading and intensity of 
ACPA responses typically marks and then follows the onset of RA suggesting an active 
contribution of these antibodies in disease development. Interestingly, ACPAs targeting 
certain citrullinated targets expand more robustly, whereas others remain permanently at low 
level suggesting a differential contribution of certain ACPA specificities to RA progression 
(45). Indeed, association with genetic risk factors or smoking was more a characteristic for 
patients with specific patterns of ACPA reactivities, instead of anti-citrulline responses in 
general (98, 99). Several monoclonal ACPAs, representing single autoreactive B cells or 
plasma cells obtained from RA patients, have been recently isolated and characterised in 
detail (100, 101).These studies have also suggested that in spite of their prominent cross-
reactivity, individual ACPA clones can be associated with unique cellular targets and 
pathological mechanisms. In addition to directly triggering cell surface receptors, ACPAs can 
contribute to inflammation and bone erosion by forming immune complexes and activating 
FcγR molecules on MФs, Dcs or developing OCs (102-104). ACPA immune complexes have 
been shown to trigger cytokine production in MФ, which effect was further stimulated by the 
presence of RF antibodies (49, 105, 106). Importantly, in addition to the constant evolution of 
ACPA fine specificities, glycosylation of the antibodies has also been shown to alter during 
disease progression, influencing binding capacity to Fc and putative lectin-type receptors and, 
consequently, the cellular effects triggered by ACPA-containing immune complexes (103) . 
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1.4 Disease propagation: pain, joint inflammation and bone destruction 
Following tolerance breaking and immune activation antibodies are present in the peripheral 
blood for several years before development of pain, joint inflammation and bone destruction. 
1.4.1 Pain 
Pain, an unpleasant sensory and emotional experience that is associated with actual or 
potential tissue damage and it represents one of the main reasons why patients seek medical 
attention (107). Pain can be classified as acute and chronic pain and based on the underlying 
pathophysiology it can be divided to nociceptive and neuropathic pain. Pain without 
identifiable physical or physiological source can be classified as idiopathic pain. Peripheral 
sensitization due to inflammation or injury can increase pain sensitivity for a long period of 
time (108). This can be due to the hyperalgesia, a hallmark of inflammation, which is 
increased pain sensitivity to normal pain stimuli and allodynia, which is pain in response to 
otherwise non-painful stimuli (109). Peripheral sensitization is mediated by cytokines and 
other inflammatory mediators typically released at sites of injury. Cytokines can also be 
released by astrocytes and glial cells leading to central sensitization. Acute pain involves the 
nociceptors in a localized tissue (110) whereas chronic pain involves both the nociceptive 
stimuli and the central nervous system sensitization, causing a reduction in the general pain 
threshold that leads to appearance of the hypergelsia and allodynia (111). 
Pain is a major complaint of RA patients that often develops already before disease onset 
(112). Presence of pain and specifically a certain type of pain (often describe as clinically 
suspect arthralgia) might help the rheumatologists in identifying individuals having a high 
risk for developing RA (113). A longitudinal study has indicated that ACPA-positive 
individuals having arthralgia progress more rapidly towards RA than ACPA-negative 
individuals (114). The presence of pain already before the onset of joint inflammation 
suggests that the mechanisms leading to pain might, at least partially, be dissociated from 
inflammation (115). Once the disease is diagnosed, pain is carefully followed up and 
treatment of pain is a major goal for therapy in RA.  A majority of the patients will 
experience pain improvement as the disease is controlled and they enter clinical remission but 
a not negligible amount of pain remains reported, known as remaining pain (115).  
Pain after RA onset can be related to the inflammation in the synovium (116). Sensory 
neurons innervate the knee joints and send signals to the central nervous system (109). 
Inflammatory mediators released in the joint can directly act on the peripheral sensory 
neurons and induce pain (109). In experimental arthritis, pro-inflammatory cytokines, 
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including TNF, IL-1ß, IL-6 and IL-17, have been shown to sensitize the peripheral neurons 
(117). ACPA immune complexes might contribute to arthralgia via FcγRs present on primary 
sensory neurons (118). Interestingly, TNF blocking therapy has shown to produce analgesic 
effect before reducing the local inflammation, suggesting the TNF inhibition affects the 
central nervous system (119). Accumulating evidence suggested that the pain in RA is not 
only dependent upon peripheral sensitization but it can also lead to altered central pain 
processing (120).  
1.4.2 Joint Inflammation 
Local accumulation of immune cells and cytokines leads to a synovitis. Normal synovial 
membrane is thin and consists  only few cellular layers specialized columnar FLSs with few 
scattered MФ or lymphocytes (121, 122). In the rheumatoid synovitis the lining layer 
becomes hyperplastic and might protrude into adjacent bone resulting in pannus formation 
while the sublining layer is characterized by massive cell infiltration and new blood vessel 
formation (123, 124). Pannus is a destructive tissue that is present in the interface between the 
synovium, cartilage and bone is clearly a feature of the erosive disease (125). Synovial needle 
arthroscopy is a technique used to obtain the synovial biopsy of the rheumatic patients (126). 
The synovial biopsy gives information on both the macropscopic and microscopic changes in 
the tissue (121). The macroscopic changes demonstrate the inflammation and hyperplastic 
synovial villi and the microscopic changes in the synovium reveals the accumulation of the 
cells with neo-vascularisation (121).  
The inflamed synovial tissue in RA contains heavy infiltration of the cells such as monocytes, 
fibroblasts, MФ, T and B lymphocytes, plasma cells, neutrophils, mast cells, DCs and natural 
killer cells enter through the increased number of highly activated post-capillary venules from 
the circulating blood (121, 127, 128).The MФ/monocytes are abundant and express CD14, 
CD68 and CD163 as their phenotypic markers. The synovial MФ are the major source of 
cytokines causing local inflammation and joint destruction (129). T cells express CD3 surface 
markers and are mainly CD4 positive cells found in RA synovium either as aggregates or 
infiltrates in the sublining layer (130). Fibroblasts are resident cells able to secrete cytokines, 
enzymes and acids that contribute to the invasive nature of the rheumatoid synovium. T and 
B cells, plasma cells organize to form aggregates produce autoantibodies associated with RA 
thus involving in the disease pathogenesis (131). The infiltration of the immune cells leads to 
increased demand of oxygen resulting in hypoxia, which directly relates to macroscopic and 
microscopic inflammation, cell migration and cytokine production (132). Suggesting that the 
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hypoxia has a role in initiating the synovial inflammation (132). Changes in the synovial 
tissue has been used to predict the treatment response to the conventional and biologic 
DMARDS and to identify the drug induced changes in the synovial architecture (133, 134). 
SF reflects the pathological changes in the synovial tissue which can be seen as increase in 
the protein content in the inflamed state in comparison to the steady state (135). The changes 
in the SF is due to the increase in the cellular infiltration, synovial hyperplasia and increased 
vessels permeability (121). These changes inturn increase the levels of pro-inflammatory 
cytokines in the SF and increased local production of the ACPAs which are capable of 
perpetuating the joint inflammation.  
Cytokines are non-structural protein or glycoproteins secreted by the immune cells involved 
in cell signaling in an autocrine, paracrine or endocrine fashion. They mediate inflammation, 
tissue repair, cell growth, fibrosis, angiogenesis and immune response (136). MФ and 
fibroblasts are major source for cytokines production in the rheumatoid synovium (136). 
Previous studies on RA synovial cultures showed increased production of IL-1, when 
compared to synovium obtained from osteoarthritis pateints (137). CD4+ helper T-
lymphocytes produce two different cytokine profiles namely Th1 (cell mediated response) 
and Th2 (Humoral mediated response) (138). RA synovium has mainly a Th1 cytokine 
profile. However, some studies provide evidence to Th2 (IL-6 and IL-10) mediated 
inflammatory response (139) (140). Recently a new type of T cells called Th17 (IL-17) have 
been identified and are currently considered as important players in propagation of local 
inflammation and bone destruction (141). IL-1 and TNF-α are the major proinflammatory 
cytokines involved in the pathogenesis of the RA and act by inducing local inflammation, 
increasing inflammatory cell adhesiveness, promoting angiogenesis and bone resorption 
(140) (137). In RA, cytokine released in the inflamed tissue induces synovial fibroblasts to 
produce M-CSF in the joints (142). Increased infiltration of the MФ is synovia of the active 
RA patients (143)and treatment with the biologic drugs like anti-TNF drugs decreases influx 
of the cells from the synovia (144). Drugs targeting pro inflammatory cytokines are effective 
in patients with RA (145) (146). 
1.4.3 Bone loss 
Bone loss is a central feature of RA resulting from an imbalanced bone formation and bone 
erosion. This section focuses on the bone loss in RA, role of osteoclast in bone loss and the 
link between the immune system and bone. 
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1.4.3.1 Types of bone loss in RA  
Periarticular bone loss is characterized by a reduction of the trabecular size and number in 
the region close to the joint (147). Periarticular osteopenia detected on X rays has long been a 
well-recognised feature of established RA and part of the old classification criteria for RA. A 
large array of pro-inflammatory cells and mediators present in the inflamed synovium 
contribute to periarticular bone loss by both activating bone loss and inhibiting the new bone 
formation (148) (149) (150) (151). More recently, periarticular bone loss has been however 
reported already at disease onset (152) and in seropositive individuals at risk for developing 
but not yet having disease (152), suggesting that bone loss might be at least partially 
uncouple from inflammation. 
Systemic bone loss, osteoporosis, with an increased fracture risk is common in patients with 
longstanding RA (153) (154). The factors that likely contribute to the systemic bone loss 
include reduced physical activity, systemic effects of the inflammation and the intake of 
glucocorticoids(147) (155). It has been reported that as many as 25% of the RA patients show 
a reduced bone mineral density of the spine or hip already before treatment and that around 
10 % can be diagnosed with osteoporosis already in these early stages (156).  Recent findings 
on the ACPA positive individuals at risk of developing RA, have demonstrated altered bone 
mineral density (BMD), decrease in the bone volume and cortical bone thickness, in 
comparison to the ACPA negative individuals (152). Another study on the longitudinal 
follow-up of ACPA positive individuals confirm the findings in the pre-clinical phase of the 
disease (157).  
1.4.3.2 Osteoclasts the bone destroying cells 
Two types of cells are essential for bone biology: osteoblasts - the bone forming cells and 
osteoclasts (OC)- the bone resorbing cells. The osteoblasts are derived from the 
mesenchymal/stromal cells and function as bone lining cells. These cells are essential for 
secretion and mineralization of the bone matrix (158). Osteoblasts continuously replace the 
new matrix and mineralize the bones that are resorbed by the OCs. Maintaining the joint 
integrity needs balance between anabolic and catabolic processes affecting the bone. 
Normally the human skeleton is remodelled constantly, with around 10% of the total bone 
content  replaced every year in adult vertebrates (159). It is estimated approximately there are 
around 2 million microscopic sites, where the bone remodelling happens to maintain the 
skeletal integrity (159). OCs are the only cells capable of resorbing of bone. They are present 
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in the resorption lacunae and interface between bone and synovia(160).  Studies on OC 
activity have suggested the impaired OC activity can lead to the reduced regeneration of the 
bone with age (159). 
OCs attach to bone using αVß3 integrin and attachment results in sealing zone formation 
which separates the resorptive pit from the extracellular surface.  Next, is the ruffled border 
formation representing the active state of the OCs. OCs utilize the proton pumps to secrete 
the hydrochloric acid which acidifies the resorptive environment and activates the proteolytic 
enzymes like cathepsin K dissolving the bone. The ruffled borders are also used by OCs to 
remove the degraded products by endocytosis through vesicular formation and then 
exocytosed into the extracellular surface by the atypical membrane surface (159).  
 
Figure 3: Process of bone resorption 
Bone resorption by mature OCs is dependent on the attachment of the OC along with the 
sealing zone formation on the surface of bone, followed by the release of the acids and 
proteolytic enzymes into the lacunae lysing the bone. 
OCs can be identified by their distinguishable multinucleated morphology and they are 
known to express the tartrate resistance acid phosphatase (TRAP) in the cytoplasm, an iron 
containing enzyme common to bone and the immune system. The presence of TRAP has also 
been reported in monocytes, MФ and DC but in serum TRAP exist in two isoforms, 5a and b 
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formed by the posttranslational modification of a single gene product (161). MФ and DC 
releases TRAP in the isoform 5a whereas 5b is predominantly expressed by the OCs (161). 
TRAP enzyme activity can be detected in the supernatant of active OC cultures and it co-
relates with the activity and resorption area (162).Investigation  on the OCs led to the 
identification of proteolytic enzyme cathepsin K(163) and calitonin R(160) considered as 
more OC specific markers.   
Reports suggest that TRAP is transported in the vesicles along with the matrix degradation 
products to the basolateral surface from which where they are released (164). The resorbing 
activity carried out by the OCs is due to the reactive oxygen species produced by TRAP 
released from the ruffled borders of the OC (162, 165). The oxygen radicals produced by 
TRAP in MФ help in antigen processing before presentation (165). Studies on the normal 
bone homeostasis and calcium levels in the body have identified Vitamin D and hormones as 
major contributors for the bone remodeling. 
1.4.3.1 Role of Vitamin D and hormones in osteoclastogenesis 
Initial studies, on the Vitamin D demonstrates its  capacity to mineralize bone,   later it was 
found that the active form of the vitamin D3(1α,25(OH)2D3) stimulates bone resorption 
(166). Mice bone marrow mononuclear cells cultured in the presence of 1α,25(OH)2D3 
differentiated into functionally active TRAP positive OCs (167). It was also shown using an 
organ culture system with rat bone increased release of  prelabelled 45Ca (calcium) can be 
induced by 1α,25(OH)2D3 (168).  
Parathyroid hormone (PTH) can activate OCs indirectly by triggering their receptors 
expressed in osteoblasts, in turn leading to the increased expression of pro-osteoclastogenic 
factors (169). Continuous exposure to the PTH leads to increased bone loss whereas 
intermittent treatment with PTH increased BMD (169). The anabolic effects of intermittent 
PTH can be related to the increase in the insulin-like growth factor  (IGF) that augments the 
proliferation of the osteoblasts (170). Both PTH and Vitamin D work together to mobilize the 
Ca from the bone and conserve the Ca loss from the body(166). Human body is dependent on 
the Ca release for the function of the cells and is regulated by the bone. Foetal growth and 
lactation in females is also dependent on the mobilization of the Ca (159).   
Calcitonin, a hormone released by the thyroid gland can regulate osteoclastogenesis directly 
by binding to its receptors expressed on the OCs. It can arrest bone resorption by targeting 
ruffled borders followed by cell retraction (171).  These findings suggest that hormones and 
vitamin D has a major role in bone remodeling and calcium homeostasis.  
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1.4.3.2 The link between OC and inflammation 
In a normal individual, a fine balance exists between bone forming cells of mesenchymal 
origin (osteoblasts) and bone resorbing cells developed from hematopoietic precursors 
(osteoclasts) (172). In RA, the balance between bone formation and bone resorption is lost 
leading to bone destruction. This imbalance is partially mediated by pro-inflammatory 
cytokines. Chronic inflammation in RA contributes to the priming of the hematopoietic 
precursor cells that become more susceptible to OC formation (173). Formation of OC 
requires either differentiation of monocytes or transdifferentiation of immature DCs in the 
presence of essential factors such as macrophage colony stimulating factor (M-CSF) and 
receptor activator of nuclear factor kappa-B ligand (RANKL) (174),(175). This process is 
further sustained by pro inflammatory cytokines such as tumor necrosis factor alpha (TNF), 
Interleukin-1 (IL-1) and Interleukin-6 (IL-6) (176) abundantly produced by local 
accumulation of immune cells in the inflamed synovia.  
M-CSF is a glycoprotein that binds to the Colony stimulating factor 1 receptor (CSF-1R) 
encoded by c-fms proto-oncogene (177). M-CSF supports the  OC differentiation by up 
regulating RANK expression (178),  inducing OC precursors proliferation  and survival (179) 
(160, 177). M-CSF induced activation of the OCs is dependent on the extracellular signal-
regulated kinases (ERK) and Phosphatidylionositol 3-Kinase (PI3K) pathway (180). The 
importance of the M-CSF has been demonstrated by using the mice lacking the CSF-1R 
which exhibits osteopetrotic phenotype (180). RANKL is a TNF super family member that 
promotes OCs differentiation, expressed by the immune cells (T and B cells) (181), 
osteoblasts (182), hypertrophic chondrocytes(183), osteocytes(184) and fibroblasts like 
synoviocytes (RA-FLS) (185). RANKL binds to its receptor RANK expressed on the surface 
of OC precursors and promotes the maturation and activation of OCs (186). The binding of 
RANK to RANKL initiates the intracellular signalling through TRAF6 (TNF receptor 
associated adaptor factor 6), activation of the nuclear factor kappa B (NF-κB)  leads to 
induction of the nuclear factor of the activated T cells c1(NFATc1) which is the master 
regulator of the terminal OC differentiation (180). A natural decoy receptor called 
osteoprotegrin (OPG), able to bind RANKL, counters its effect (187). OPG binding to 
RANKL down regulates RANKL signaling. OC differentiation is regulated by the balance 
between the OPG and RANKL (188).  
Apart from the essential cytokines, osteoclastogenesis is influenced by the several other 
cytokines that can either promote or inhibit osteoclastogenesis through their direct and 
indirect effects (189).  Cytokines like TNF, IL-1, IL-6, IL-8, IL-15, 1L-17, IL-
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the osteoclastogenesis by mostly inducing RANKL production on other cells in the 
synovium, except TNF, IL-6 and IL-8 which can directly influence OC formation (189-191). 
On the contrary, IL-4, IL-10, , IL-12, IL-18, IL-27, IL-33 and GM-CSF can potently inhibit 
osteoclastogenesis (189, 190).  
 
Figure 4: Inflammation induced bone loss 
In the inflamed synovium, several proinflammatory mediators and activated cells such as 
fibroblasts and lymphocytes are present. These cells induce bone loss by directly releasing 
pro-osteoclastogenic cytokines stimulating cells increasing the differentiation OC precursor 
cells to into OCs thereby damaging bone. 
Autocrine and paracrine signalling in OC development and functioning capacity has been 
implicated in the normal and pathological bone remodelling. One of the key mediator of the 
autocrine signalling in osteoclastogenesis is IL-8, which is regulated by RANKL and other 
pro-inflammatory cytokines involved are IL-6, TNF and IL-1 (192, 193). Though other 
cytokines can also be secreted by OCs, the magnitude of the IL-8 production is very high in 
the OC culture supernatants (193). Moreover, inhibiting IL-8 or the IL-8 receptors 
(CXCR1/2) during the OC development significantly reduced the OC formation (192). 
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Interestingly, circulating levels of the IL-8 is associated to the osteolysis in breast cancer 
metastasis patients (194). These findings on IL-8 suggest that it is an important autocrine 
factor which is essential for the OC development and functioning linked to pathological bone 
loss. 
In addition to the RANK signalling, co-stimulatory pathways play an important role in 
osteoclastogenesis (195). Co-stimulatory molecules such as osteoclasts associated receptors 
(OSCAR) and paired Ig-like receptor-A(PIR-A) transmit their signal through with the FcγR 
chain associated adaptors (190). On the other hand, TREM2 (Triggering receptor expressed 
on myeloid cells) and MD-L1 (Myeloid Dap-12 associated lectin) are the other co-
stimulatory molecules that are associated with DAP-12 (DNAX associated protein 12D size) 
(195).  The importance of the co-stimulatory molecules has been characterized either by 
blocking these receptors or loss of function of their genes which impairs osteoclastogenesis 
(195).  
1.4.3.3 The link between the bone and the immune system 
To gain insight on how the immune system orchestrates bone formation and resorption, we 
need to understand the interplay between the bone and the immune system, which led to 
coining of the term ‘osteoimmunology’(196). Immune cells and bone cells are known to 
exchange signals in the form of cytokines and receptor signalling. Osteoclastogenesis is one 
of the key event that is dis-regulated in the autoimmunity and this leads to increase in the 
bone erosion. Several studies on the T and B-cells have increased our understanding on the 
signals that arise from the adaptive immune systems that contribute to the bone remodelling. 
For instances, T cells can promote and inhibit osteoclastogensis. Activated T helper cells are 
known to promote bone destruction by directly by expressing RANKL in RA (197) and they 
can secrete cytokines like IL-17 which is known to indirectly augment osteoclastogensis 
(198).  On the contrary, Foxp3 expressing T regulatory cells can inhibit the osteoclastogensis 
by secreting the IL-10, IL-6 and IFNgamma(199).  
OCs are considered as the innate immune cells due to their capacity to express 
immunoreceptors, present antigens, sense the TLR mediated immunity (200). Activated B-
cells are known to secrete pro-osteoclastogentic factors and they can support the development 
and activation of OCs  (201). Synovial tissues and the SF is an important source of RANKL 
producing Fc-receptor-like-4(FcRL4) B-cells and activated T-cells contributing to the bone 
destruction in RA (197, 202). Interestingly, presence of autoantibodies against the 
citrullinated and carbymaleted targets are linked to the severe radiological progression  
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suggesting that B cells can regulate osteoclastogensis (203) (42). Altogether these studies 
demonstrate the role of lymphocytes in regulating OCs both in the pre-clinical phase and the 
clinical phase of RA.  
Prevention of bone destruction is an important aspect of the treatments for the RA patients. 
To further understand the link between the immune system and the bone, the therapies 
developed to target adaptive immunity can have direct and indirect effect in protecting the 
bone. Rituximab targets CD20 positive B cell and depletes those in RA patients, known as 
effective in treating the seropositive RA patients (204). Rituximab has been reported to 
abrogate the joint destruction indirectly by decreasing the synovial RANKL expression and 
the OC precursors population (205). Clinical studies with abatacept (CTL4 Ig) have reported 
that they are efficient in controlling the symptoms of RA and importantly a bone sparring 
effect (206). In relation to the clinical studies with abatacept,  in-vitro studies using CTLA4 
directly on the monocyte derived OCs abrogates the OC formation (207). These findings 
indicate a major link between the immune system and the bone. 
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2 AIM 
The overall aim of my thesis is to investigate the pathogenic role of ACPA with a focus on 
bone destruction and pain induction. Specific aims are 
1. To investigate the capacity of ACPAs to induce osteoclastogenesis  
2. To investigate the capacity of ACPAs to induce pain-like behaviour in-vivo 
3. To investigate the role of citrullination in OC development 
4. To investigate the role of DCs transdifferentiation in OCs 
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3 MATERIALS AND METHODS 
3.1 Patients 
Informed consent was obtained from the RA patients at the Rheumatology Clinic at 
Karolinska Unviersity Hospital, Stockholm, Sweden. ACPAs were purified from Synovial 
Fluid (SF)(n=26) and Plasma (n= 38) from anti-CCP2 antibody positive RA patients fulfilling 
the American college of the Rheumatology (ACR)/ European League Against Rheumatism 
(EULAR) criteria for RA. For OC assays, blood was obtained from (n=6) ACPA positive RA 
patients. The regional ethics committee at Karolinska Institutet approved the study.  
3.2 ACPA production (Paper I, II and III) 
Isolation of the polyclonal ACPAs was performed using initial purification of the total IgG 
from the SF and Plasma of RA patients followed by ACPA IgG affinity purification on CCP2 
columns as described previously (208). Non-ACPA IgG fraction (FT) is used as the control 
for the all experiments involving polyclonal ACPAs. Further, SF and PB ACPAs were 
characterized for peptide epitope recognition using a multiplex chip-based assay (Paper I). 
Monoclonal ACPAs and control monoclonal antibody were generated using single B-cell or 
plasma cell isolated from RA patient SF. Followed by the isolation, immunoglobulins were 
cloned and expressed in human kidney embryonic fibroblasts (Gibco Invitrogen) or expi293 
cells (Thermo Fisher scientific). The expressed antibodies were purified using protein G 
isolation column. Antibody reactivity was characterized by the reactivity to the citrullinated 
epitopes using multiplex microarray or ELISA. All of the antibody preparations were 
endotoxin free.  
3.3 Osteoclasts cultures and Bone resorption analysis (All papers) 
To study the effect of autoantibodies on osteoclastogensis, we first isolated monocytes from 
healthy blood donor buffy coats or from the peripheral blood (PB) of patients with ACPA-
positive RA patients, by ficoll separation followed by positive selection with anti-CD14 
microbeads. Either MФs or iDC were generated form these monocytes. MФ were generated 
by 3 days M-CSF stimulation of monocytes and further developed into OCs in the presence 
of M-CSF and RANKL. iDC were generated 6 days GM-CSF and IL-4 stimulation of 
monocytes and further developed into OCs in the presence of M-CSF and RANKL. 
Additionally, CD1c+ iDC were isolated from healthy donor buffy coats, using a CD1c+ DC 
isolation kit (Miltenyi Biotec Norden AB, Lund, Sweden) and further developed into OCs 
using in the presence of M-CSF and RANKL. For studies of osteclastogenesis in mice, 
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CD11b+ bone marrow cells were isolated using CD11b+ isolation kit (Miltenyi Biotec Norden 
AB, Lund, Sweden) and further developed into OCs in presence of murine M-CSF and 
RANKL. In both human and mice experiments, OCs were identified by light microscope as 
tartrate-resistant acid phosphatase (TRAP) positive cells with at least 3 nuclei.  
 
 
Figure 5: Schematic representation of OC development from peripheral blood monocytes 
derived MФ and DC as precursors in the presence of ACPA. 
To study the function of the OCs, we used an in-vitro model of bone erosion using an 
artificial bone surface, coated with inorganic crystalline calcium phosphate that mimics the 
physiological bone (Osteassay surface, catalogue number CLS 3988, Corning, NY, USA). 
MФs and iDCs obtained were developed into OCs (as describe above) on these artificial bone 
surfaces. At the end of the culture OCs were removed and erosion zones were visualized 
under light microscope. Erosion area was estimated as percent of total area by NIS-elements 
basic research (Nikon, Amsterdam, Netherlands) 
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Cell culture supernatants from the TRAP assay were analysed for the cytokines using 
cytometric bead array (CBA). 
3.4 Mass spectrometry (Paper III) 
Mass spectrometry (MS) was used to study the proteome difference between MФ- and iDC-
derived OCs and to identify the citrullinated proteins.  Whole cell lysates from OCs generated 
from MФ- and iDC-precursors were used for the analysis. Protein concentrations were 
determined followed by trypsin digestion.  Samples were analysed using Easy-nLC 
chromatography system directly coupled linked online to a Q Exactive mass spectrometer. 
Principal component analysis (PCA) was performed on the resulting proteome list after 
applying 1% false discovery rate (FDR). Label-free method was used to identify citrullinated 
proteins in our samples based on the 0.98 Da mass difference between citrulline and arginine 
detected in LC-MS/MS analysis. To avoid misidentification of the peptides, we visually 
inspected and validated the spectral fragmentation pattern of the citrullinated peptides. 
3.5 PAD activity (Paper I and III) 
PAD enzyme activity in the cell lysates was measured using the commercially available 
ELISA kit measuring the amount of arginine that have been deiminated. PAD enzyme 
activity was determined by correlation against the control recombinant human PAD4 enzyme 
activity. 
3.6 Immunohistochemistry and Immunofluorescence (Paper I, II and III) 
PAD enzymes and citrullinated protein expression was analysed using both permeabilized 
and non-permeabilized staining procedure of OCs cultured on glass slides and mice joint 
tissue sections. Commercially available and in-house engineered monoclonal antibodies were 
used and visualized with fluorescent dyes or 3,3′-Diaminobenzidine tetrahydrochloride 
hydrate (DAB) using confocal microscope and light microscope respectively. 
3.7 Animal Experiments (Paper I and II) 
Experiments involving mice were approved by local ethical committee for animal 
experiments Stockholm, Sweden. Adult male Balb/c mice were used to investigate the in-vivo 
effect of ACPAs. Animals were injected intravenously with either ACPA IgGs or murinised 
monoclonal ACPAs and respective control IgGs. To assess the mechanical sensitivity, mice 
were acclimatized on top of mesh like surface and optiHair filaments were applied under the 
paw until buckling of the hair filament occurred. Positive response was determined using the 
spontaneity of withdrawal within 2-3 seconds and 50 % withdrawal was calculated using 
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Dixon up-down method.  At the end of the experiment mice were euthanized and tibia from 
left hind leg was used for bone structure was analyzed using a sky scan micro-CT 
(microcomputer tomography). Trabecular bone in tibia which is located 644µm from 
proximal growth plate and extending 100,5µm was assessed for bone mineral density (BMD) 
and 3D analysis. Volume of cortical bone in tibia measuring 617µm in length, located in the 
distal tibia was analyzed for tissue mineral density(TMD) and 3D analysis, by CT Analyser 
software (version 1.14.4.1; Bruker). 
3.8 Flow cytometry (Paper III and IV) 
MФs and DCs were analyzed for the phenotypic markers using commercially available 
antibodies conjugated with flourochromes and the data was analyzed using Flow Jo software.
  
3.9 Statistical analysis (All papers) 
Kruskal-Wallis test followed by Dunn’s multiple comparison and one-way ANOVA followed 
by Holm-Sidaks post hoc test were used for non-parametric and parametric comparisons of 
three or more groups. Two-way analysis of variance followed by Bonferroni post hoc test 
was used for repeated measurements comparing changes over time. Graph Pad prism 6 
software was used for the all the statistical analysis. Probability (P) values less than 0.05 were 
considered significant. 
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4 RESULTS AND DISCUSSION 
Bone destruction and pain are important clinical features in RA. Pain in the joints without 
clinical inflammation, known as arthralgia, in combination with ACPA positivity has been 
shown to be highly predictive for RA development (209, 210). ACPAs are present in the 
blood long before the onset of  RA (41) and are a major risk factor for developing bone loss 
even in the absence of clinical signs of inflammation (152, 203). We aimed to investigate the 
role mechanistic link between the ACPA positivity, bone destruction and pain. 
4.1 Polyclonal ACPAs enhance osteoclastogenesis and bone resorption in 
vitro 
To test ACPAs effects on OCs, we first used polyclonal affinity purified ACPA derived from 
the peripheral blood and synovial fluid of RA patients. As expected, polyclonal ACPA 
showed broad reactivity against several citrullinated targets including several citrullinated 
epitopes in vimentin, enolase and fibrinogen. Polyclonal ACPAs but not control non-ACPA 
IgGs, enhanced the number of MФ-derived OCs and their bone resorptive capacity. The 
effect was equally potent from MФ -derived OCs originating from both healthy individuals 
and ACPA-positive RA patients. For OCs originating from ACPA-positive RA patients, 
polyclonal ACPAs increased the OC numbers by a fold of 1.8±0.6 (mean±SEM) and bone 
resorption by a fold of 2.3±0.7 (mean±SEM) when compared to non-ACPA IgGs (p<.0.05, 
figure 6A and B). We further investigated if the effect of polyclonal ACPA was dependent on 
OC cell precursors by testing ACPAs effect on the OC transdifferentaition of both in vitro 
generated healthy donor monocytes-derived iDC and healthy donors blood isolated CD1c+ 
iDC.   
We next wanted to investigate if ACPA effect is dependent on the cellular type of OC 
precursors. As beside MФ, iDC have been previously described as potent OC precursors we 
investigated the capacity of polyclonal ACPA to enhance osteoclastogenesis from in vitro 
developed iDC originating from healthy donors. Similar to MФ precursors, ACPA IgGs were 
able to promote osteoclastogenesis from iDC precursors with a significant increase in both 
OC numbers (a fold increase of 2.3±0.9, p<0.05, figure 7A) and bone resorption area (a fold 
increase of 2.6±0.9, p<0.05, figure 7B) compared to control IgGs. Principal component 
analysis on the cell proteome confirmed that the iDC and MФ precursors have distinct 
proteomic signatures while OC derived from either of these precursors have indistinguishable 
proteomic signatures (Paper III). To further test the reproducibility of the model and to mimic 
a putative in vivo situation, circulating myeloid DC precursors, CD1c+ DCs, were isolated 
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from blood of healthy individuals and stimulated with ACPAs. We were able to demonstrate 
for the first time that also circulating iDC are capable of OC transdifferentiation and this is 
enhanced by ACPA in a similar manner as for MФ and in vitro developed iDC (Paper III). 
 
 
Figure 6: ACPAs promote osteoclastogenesis and bone resorption 
MФ-derived OCs generated from ACPA positive RA patient B. (A) TRAP positive OCs 
treated with PB-derived polyclonal ACPAs or control IgGs. (B) Bone resorption by OCs 
generated on the calcium phosphate surface. Graphs represent the fold difference in OC 
number and erosion area in the presence of 0.1 and 1 µg/ml of IgGs or ACPAs. *p<0.05. 
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Figure  7: ACPA increases iDC transdifferentiation into OCs  
iDC-derived OCs generated from peripheral blood of RA patients in the presence of control 
IgGs or ACPAs. The number of OCs analyzed using (A) TRAP staining (100X 
magnification) and (B) calcium phosphate bone resorption assays. Images were obtained 
using light microscopy and graphs represent the fold-difference (normalized using 
untreated M-CSF/RANKL controls) in OC numbers (TRAP-positive cells with ≥3 nuclei) 
and in resorption areas (n=3 independent experiments).  
Taken together our findings show that polyclonal ACPA with broad specificities are able to 
enhance osteoclastogenesis and bone resorption independent of what type of OC precursors 
are used (either MФ or iDC derived, either healthy donors or RA patients derived). This is in 
agreement with others studies showing that also more restricted polyclonal ACPAs such as 
antibodies against MCV are able to promote MФ derived osteoclastogenesis (102). However, 
due to the large number of cit specificites recognized by the polyclonal ACPA it is impossible 
to predict which individual or combination of specificities is responsible for this effect. Based 
on our iDCs findings it is tempting to speculate on a role for these cells in RA-associated 
bone loss. Increased frequency of DCs are found in SF of RA patients with a decrease in DC 
levels in circulation (211). It appears that DC migrated into the joint might have the capacity 
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to switch from their conventional function of antigen presentation to undergo 
transdifferentiation in to OCs in the presence of ACPAs. In line with this hypothesis it has 
been shown that both immature and more mature DCs express RANK, an essential molecule 
for OC differentiation and maturation  (212, 213).  
4.2 Some but not all monoclonal ACPAs enhance osteoclastogenesis 
In order to further investigate the relevance of epitope recognition and antibody traits for the 
above described effect we went on to test the effect of of monoclonal ACPAs obtained by 
single B cell cloning from the SF of RA patients. Interestingly, while monoclonal ACPAs had 
a more limited reactivity they still showed significant cross-reactivity with different patterns: 
1325:01B09 (CCP1, Cit-Fibb36-52 and Cit-Fib563-583) and 1325:04C03 (CCP1, Cit-Vim60-75 and 
Cit-vim2-17) (see figure 8). Importantly none of the ACPA monoclonal showed any kind of 
reactivity towards native non-modified targets. This characteristic of monoclonal ACPAs 
have been now reported in others studies from our laboratory (101). Out of four tested 
monoclonal ACPAs, two were able to enhance osteoclastogenesis and bone resorption while 
two others failed to do this (Paper I).  Importantly again neither E02, an irrelevant antibody 
directed against an epitope of the tetanus protein, nor a RF (un-published, see figure 9), both 
isolated using the same methodology as for the monoclonal ACPAs had any effect on OCs. 
This data taken together show that antibody traits and recognition patterns are important. 
However due to the above described cross-reactivity it is difficult to speculate on the exact 
specificity or specifcities that are and those that are not related to the ACPA 
osteoclastogenetic effect.  Notably, ACPAs that induced osteoclastogenesis reacted with the 
immunodominant cit-epitopes of vimentin (Vim60-75) and enolase (CEP1) along with other 
epitopes, while ACPAs that failed to induce OC mainly reacted with other epitopes such as 
those derived from fibrinogen. 
We than wanted to investigate if the observed in vitro effect has relevance in vivo. To do this 
we injected monoclonal ACPAs into Balb/c mice and evaluated bone loss by micro-CT. 
Confirming the in vitro observations ACPA injection in mice induced significant trabecular 
bone loss and some occasional cortical erosions (see figure 13) 
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Figure 8: Specificity pattern of monoclonal ACPAs 
ACPA reactivity pattern as analyzed on a multiplex microarray of RA associated peptides 
(214). Peptide binding is indicated by grey color. 
 
Figure 9:  Rheumatoid Factor IgG has no influence on osteoclastogenesis 
MФ-derived OCs generated from healthy donor buffy coat. (A) TRAP positive OCs treated 
with RF IgG and bar graph represents the OC numbers.  
4.3 ACPAs effects on OC are dependent on protein citrullination  
As ACPA but no other control antibodies were able to mediate osteoclastogenesis, we 
hypothesized that protein citrullination in OCs might be a previously unrecognized regulatory 
mechanism for osteoclastgenesis. We first tested if ACPA are able to bind to OC being able 
to demonstrate that ACPA but not the non-ACPA antibodies are able to bind targets 
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expressed on the surface of non-permeablised OC suggesting that citrullinated target on the 
surface of OCs might be the initiating step in ACPA-mediated osteoclastogenesis (Paper I). A 
previous report had shown that cit-vimentin can be identified by label free MS in MФ derived 
OC (102). Using a similar approach, we also investigated presence of cit targes in iDC 
derived OCs and showed that three citrullinated beta-actin peptides were identified in iDC 
precursors, while the mature iDC derived OCs expressed an increased number of citrullinated 
peptides, eight being beta-actin peptides and six vimentin peptides (Table A in figure 10). To 
confirm this with than studied if ACPAs can bind to either actin or vimentin on the surface of 
OC. Indeed, ACPA co-localised with antibodies detecting either vimentin or actin (figure 
10B). while these finding point to a potential role of cit actin and vimentin, it is important to 
note that other cit targets derived from low abundant proteins might have been missed in our 
MS screening.   
 
Figure 10: Identification and validation of citrullinated proteins in iDCs and OCs 
(A.) Table representing citrullinated peptides identified in iDCs and OCs. Numbers indicate 
the highest mascot score obtained for each peptide and blank spaces indicating undetectable 
citrullinated peptide. (B) OCs double stained for vimentin or actin respectively in green, 
together with monoclonal 1325:04 C03 ACPAs in red with nuclear staining using DAPI in 
blue. Representative confocal microscope images analyzed using image J for co-localization 
analysis in grey and r is the correlation coefficient.  
Peptide Sequence Amino acid iDC OC
Beta-actin 
AGFAGDDAP(Cit)AVFPSIVGRPR 19-39 28 26
AVFPSIVG(Cit)PR 29-39 10
(Cit)GILTLK 62-68 46
IWHHTFYNEL(Cit)VAPEEHPVLLTEAPLNPK 85-113 41 46
ILTE(Cit)GYSFTTTAER 192-206 41
GYSFTTTAE(Cit)EIVR 197-210 44
DLYANTVLSGGTTMYPGIAD(Cit)MQK 292-315 11
QEYDESGPSIVH(Cit)K 360-373 31 37
Vimentin
SLYASSPGGVYAT(Cit)SSAVR 51-69 68
NT(Cit)TNEKVELQELNDR 98-113 124
DV(Cit)QQYESVAAK 271-282 44
FADLSEAAN(Cit)NNDALR 295-310 42
KLLEGEES(Cit)ISLPLPNFSSLNLR 402-424 42
LLEGEES(Cit)ISLPLPNFSSLNLR 403-424 39
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Being able to identify citrullinated targets in OC, we than investigated the expression patterns 
for the enzymes that are responsible for citrullination of protein, namely peptidyl arginine 
deiminases, focusing on PAD2 and PAD4 that have been previously identified in monocytes, 
MФs and the inflamed rheumatoid tissue (68, 215). Both enzymes were present in OC 
precursors with an increase in PAD2 and decrease in PAD4 expression in mature OCs (Paper 
I and III). Further, significant PAD activity was detected in both OC precursors and more 
mature OCs (figure 10A). Presence of citrullinated targets and active PAD enzymes in OCs 
together with the original observation that ACPA promote OC differentiation and maturation 
prompt us to investigate if PAD enzymes are involved in ACPAs effects.  To this end, we 
tested the effect of a pan PAD inhibitor, Cl-amidine, on OC differentiation in the presence 
and absence of ACPA. To our surprise Cl-amidine inhibited OC differentiation even in the 
absence of ACPA and despite high RANKL concentration, suggesting that PAD activity is 
essential for the physiological development of OC (figure 10B). Interestingly, Cl-amidine did 
not affect the functions of other cells such as synovial derived fibroblasts (Paper I). 
Taken together these findings suggest that the OCs but no other cells are dependent on 
citrullination and PAD activity for fulfilling their physiological role. Such a tentative unique 
feature of OCs might explain the presence of citrullinated proteins on the OCs during their 
normal differentiation, in contrast to most other cells that express citrullinated proteins only 
in an inflammatory milieu (216). This dependency on PADs and citrullination for normal OC 
differentiation might therefore be linked to preferential targeting of OCs by ACPAs in a non-
inflammatory context. This scenario is further supported by the observation that Cl-amidine 
was able to inhibit ACPA-induced osteoclastogensis as well. As such high Cl-amidine doses 
completely block ACPA-induced ostelcatogenesis, while lower doses of Cl-amidine (0.2µM 
for MФ-derived osteoclastogenesis and 2µM for iDC derived osteoclastogenesis) blocked 
only ACPA-induced osteclastognesis but not basal (RANKL dependent) osteoclastogenesis 
(figure 11 C and D). 
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Figure 11: Citrullination and PAD enzymes are essential for OC differentiation and 
ACPA-mediated osteoclastogenesis. (A) PAD activity was measured in MФ- and DC- 
derived OC cell lysates. Bar graph represents the PAD activity expressed in mu per mg (n≥3 
independent donors) (B) Osteoclastogenesis with 5, 25 and 50 ng/ml of RANKL in the 
presence of 10 ng/ml M-CSF with and without PAD inhibition (20µM).   (C and D) ACPA-
effect on MФ- and DC- derived osteoclastogenesis in the presence of PAD inhibitor. Bar 
graphs illustrating the fold difference in OC numbers based on TRAP staining (n≥3 
independent experiments). *p<0.05 
4.4 ACPA activate osteoclstogenesis through and IL-8 dependent 
mechanisms 
To further explore potential cellular mechanisms responsible for mediating ACPAs effect we 
measured a panel of cytokines in OC culture supernatants. Of several investigated mediators, 
IL-8 concentrations were increased in the presence of ACPA but not control non-ACPA IgG 
(figure 12 A and B). It has been previously shown that IL-8 is able to promote 
osteoclastogenesis by an autocrine mechanism and we show here evidence that this 
mechanism might be involved in ACPA induced osteoclastogensis. Confirming this, IL-8 
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blocking by monoclonal neutralising antibody abolished the ACPA-mediated 
osteoclastogenesis (figure 12 C). We then proceed to investigate if IL-8 mediates ACPAs 
effect in in vivo model. To this end we injected ACPA in mice in the presence or absence of 
reparixin a CXCR1/2 inhibitor blocking the effect of CXCL1 and 2, the mouse homologues 
for IL-8. Confirming the in vitro result reparixin was able to abolish ACPA-induced 
trabecular bone loss as measured by micro CT (see figure 13) 
 
Figure 12: ACPA increases IL-8 levels during osteoclastogenesis 
 (A and B) Graphs representing the IL-8 levels measured in supernatants from IgG or ACPA 
treated MФ and DC derived OCs. (C) OC culture in the presence of IgGs or ACPAs with and 
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without IL-8 neutralizing antibody (1 µg/ml) (C) Graphs illustrating the fold difference in OC 
numbers monitored using TRAP staining. *p<0.05. 
 
Figure 13:  Systemic ACPA-induced bone loss is neutralized by reparixin targeting 
CXCR1/2.  A) Micro-CT images in 2D representing changes in tibial bones of mice injected 
with saline, (B) ACPA and (C) ACPA followed by reparixin treatment. Graphs representing 
(D) trabecular bone mineral density (BMD), (E) trabecular number, (F) trabecular bone 
volume (BV/TV) and (G) cortical trabecular mineral density (TMD). *p<0.05.  
4.5 ACPAs induce pain-like behavior in mice 
As ACPAs and bone loss are present in individuals at risk for developing RA presenting with 
arthralgia, we aimed to investigate a potential connection between ACPA, bone loss and pain. 
To do this we used a mechanical sensitivity model developed to study pain in mice. Mice 
were administered i.v. with either human polyclonal ACPA, control IgG (FT) or saline and 
the mechanical sensitivity was followed for 7 or 28 days. ACPAs induced pain-like behaviour 
in mice with significantly lower tactile threshold at all time points from day 1 as compared to 
non-ACPA IgG and saline treated mice (figure 14A and C). As ACPAs stimulate OC to 
produce IL-8 and IL-8 is a known pain-inducer molecule we hypothesize that IL-8 might be 
the link between ACPA-activated OCs and pain. To test this CXCL1/2 is known to induce 
pain-like behaviour in mice by binding CXCR2 expressed on the peripheral and nociceptive 
neurons (217). 
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We sought to determine the link between the bone loss and pain performing 
immunofluorescence stainings on the sub-chondral bone of mice using polyclonal ACPAs 
and anti-CD68 antibodies.  Strikingly, ACPAs specifically co-localised with the CD68 
positive MФ, possibly OC precursors in the bone marrow with no affinity to synoviocytes, 
osteocytes, chondrocytes or endothelial cells (figure 14B). Furthermore, the double positive 
CD68/ACPA OC precursors were in close proximity with the CGRP positive sensory fibres 
in the bone marrow (Paper II), providing a putative link between OC-derived CXCL1/2 and 
sensory nerve stimulation. It is important to mention that in-vitro generated OCs from mice 
bone marrow cells, stimulated with ACPA, increased the CXCL1 production in joints and 
increased CXCL1 and 2 levels were observed in ankle joint extracts from mice injected with 
ACPAs (Paper II). 
 
Figure 14: Mechanical sensitivity measured in mice after intravenous administration of 
human polyclonal ACPA and murinised monoclonal ACPA.   
Saline, IgG from healthy donors, IgG from RA patients (FT) or polyclonal human ACPA was 
injected in equal amounts (1 mg per mice). A) Mechanical sensitivity was monitored for 7 
days.  (B) Microscopic images representing the sub-chondral mice bone marrow stained for 
OC precursors (CD68) in green and ACPA in red followed by the co-localization of ACPA 
with CD68 positive cells in white (indicated with white arrows). (C) Mechanical sensitivity 
A.	
C.	
B.	
D.	
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induced by ACPA monitored for 28 days with (D) sub-cutaneous injections of reparixin 
(30mg/kg/day) between day 6 to 12.  
To mitigate the pain induction mediated through CXCL1/2, we injected mice with 
monoclonal ACPAs (clones D10 and B02) and treated with CXCR1/2 antagonist reparixin 
for six consecutive days. Importantly, reparixin treatment partially reversed the ACPA-
induced mechanical sensitivity, demonstrating that the attenuation of pain is dependent on the 
ACPA-mediated chemokine release by OCs (figure 14D).  
In summary, we demonstrate that ACPAs promote bone loss and pain like-behaviour by 
inducing IL-8 both in vivo and in vitro. We show that ACPAs might bind to OCs in bone 
marrow which are localized near the CGRP positive sensory neurons and that the blockade of 
CXCR1/2 reduces the ACPA-induced hypersensitivity. Blocking IL-8 can also inhibit 
osteoclastogenesis and prevents ACPA-induced bone loss.   
However, it is important to point out that ACPA administration alone did not lead to arthritis 
development indicating that ACPA-dependent arthritis-development might need a second hit 
causing inflammation. Moreover, the identification of ACPA targets on OCs and precise 
downstream signalling pathways remain to be explored. It has been previously reported that 
the anti- mutated citrullinated vimentin  (anti-MCV) (Fab)2 fragments, generated by pepsin 
digestion, induced an increase in OC numbers  (102). In our study, we used Fab fragments of 
the monoclonal ACPAs D10 and B02, which induced an increase in osteoclastogenesis 
(Paper I). This indicates that the ACPAs binding on citrullinated antigens expressed on the 
OC surface, play an important role in enhanced OC maturation and activation. 
ACPA immune complexes have been shown to induce TNF production in MФs (218). MФs 
and OCs express Fc receptors on the cell surface and depending on the antibody isotype these 
immune complexes may activate or inhibit osteoclastogenesis (219). Recently, it has been 
reported that the presence of  ACPA together with RF, additively increased the association 
with  bone erosion in RA patients while RF alone was not associated with erosion size (220, 
221). Interestingly, in agreement with this we demonstrated that RF IgG alone did not 
influence the OC development in vitro. It is tempting to speculate that the ACPA and RF 
immune complexes would further augment the ACPA-induced OC leading to increased bone 
erosion in RA. Our findings suggest that the Fc and the antigen binding Fab fragments have 
an independent role in OC maturation, but additional studies are needed to understand the 
complex role of antibody-mediated osteoclastogenesis. 
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The pain-like behaviour was inducible using both the human polyclonal- and murinised 
monoclonal ACPAs originating from RA patients, demonstrating that pain induction in mice 
is not due to adverse reaction against human protein. In in-vitro OC experiments monoclonal 
ACPA Fab fragments were efficient to induce osteoclastogensis and enhance IL-8 
production, demonstrating the importance of antigen antibody interaction (Paper I). It would 
be interesting to use ACPA Fab fragments in the pain-behaviour model to identify the 
importance of pure antigen-antibody-mediated effect. 
To study the direct effect of ACPA on sensory neurons, we further investigated the effect of 
ACPAs on the peripheral neurons in in vitro cultures. ACPA-treatment did not affect the 
calcium in flux/ signalling in neurons (Paper II) suggesting that OCs are identifiable key 
targets for the ACPA-mediated IL-8 release. ACPAs precede the onset of RA but not all 
individuals with ACPAs report pain in the joints. Retrospective epidemiological studies on 
ACPAs report that over the years an increased antibody epitope recognition and increased  
ACPA titres close to the clinical disease development (222), indicating that certain ACPAs 
might be responsible for pain induction. In future, our animal model could be used to address 
this interesting question by using ACPAs from those individuals that report pain and those 
that are ACPA positive without pain.  
Taken together, this study provides novel mechanism for ACPA-induced bone loss and pain 
signifying the potential pathogenicity of these autoantibodies. ACPAs are known to precede 
the clinical signs of RA and several studies have confirmed the occurrence of bone loss in 
ACPA positive individuals at risk of developing RA (152, 203, 223). Our findings suggest 
that ACPAs are not only bystander antibodies but actively involved in the OC activation in 
RA. Therefore, alleviation of pain symptoms in ACPA positive individuals by IL-8 blocking 
may decrease the ACPA-mediated OC activation and thus be a potent treatment to prevent 
RA development. 
4.6 Lactic acid influences the dendritic cells transdifferentiation in to 
osteoclasts   
Synovial cell accumulation enhances the consumption of oxygen leading to hypoxia in the 
joints (224). Additionally, activated Th1 or Th17-type lymphocytes, inflammatory MФs or 
activated DCs turn towards glycolytic energy production, which facilitate biosynthetic 
processes and cytokine production. Acidiosis is a phenomenon of decreased pH, occurring 
due to the metabolic shift associated with hypoxia and immune activation (225). In RA, 
elevated levels of lactic acid have been observed in the inflamed joints (226). DCs or their 
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progenitors are recruited into the inflamed joints and contribute to antigen presentation and 
the production of pro-inflammatory cytokines or, alternatively, DC can also transdifferentiate 
into OC  (175, 227). We aimed to study role of acidosis in the differentiation switch between 
inflammatory or OC-prone DC subsets.  
We have observed a cell concentration-dependent reprogramming of monocyte-derived DC 
differentiation that was influenced by the amount of lactic acid in the cell culture supernatant 
(paper IV). DCs developing in sparse cultures (0.125x106 and 0.5x106 cells/ml) 
homogenously expressed CD1a whereas DCs from dense cultures (2x 106 cells/ml) expressed 
both CD1a and CD14 (figure 15A). DCs developing in sparse cell cultures had higher 
capacity to produce inflammatory cytokines, to induce Th1 polarization, and to migrate 
towards the lymphoid tissue chemokine CCL19. On the contrary, activated DCs originating 
from the dense cultures produced IL-10 but no inflammatory cytokines (Paper IV).  
Next, we investigated whether the different DC types obtained from dense and sparse cultures 
could trans-differentiate into OCs in the presence of M-CSF and RANKL. Interestingly, 
despite their non-inflammatory phenotype, DCs from dense cultures were more prone to 
develop into OCs and possessed higher bone resorption capacity (figure 15 B and D). To 
understand the mechanism that promoted different DC phenotypes in dense and sparse 
cultures, we added day-2 supernatants from dense to sparse cultures. In response to this 
treatment a clear downregulation of the CD1a+CD14– expression profile was detected, even 
when only the <3KD fraction of the supernatant was used, suggesting a non-protein type 
mediator (Paper IV). Previously, it has been reported  that lactic acid, produced by cancer 
cells can  inhibit the development of IL-12 producing CD1a+CD14- DCs (228). Interestingly, 
we detected similar lactic acid concentrations in dense DC cultures as previously observed in 
the case of cultures tumor cells (Paper IV).  
To understand the role of endogenous lactic acid in the autocrin regulation of DC 
development we pre-treated DC precursors with oxamic acid, an inhibitor of glycolysis, or 
provided galactose instead of glucose in the cell culture medium. The reduced glycolytic 
activity increased the IL-12 producing capacity in the developing cells but interfered with 
their ability to transdifferentiate into OCs, suggesting a key role for lactic acid in the 
differentiation plasticity of DCs (figure 15D). Furthermore, the capacity of DCs to develop 
into OCs correlated with their endogenous PAD activity and the level of protein 
citrullination, indicating that the DC-OC transition could also be regulated by protein 
citrullination. Moreover, DCs that turn towards the OC-prone lineage might also be sensitized 
to the ACPA-mediated boost in OC development (Paper III). 
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Figure 15: Cell culture density influences iDC transdifferentiation in to OCs.                      
(A) Contour plots represent CD14 and CD1a distribution on monocyte-derived DCs 
generated in dense or sparse cultures (2x106, 0.5x106 and 0.125x106 monocytes/ml). The 
different DC types were trandifferentiated into OCs in the presence of M-CSF and RANKL. 
(B) OC development was monitored with the help of TRAP staining (B) or a bone resorption 
assay using calcium-phosphate surface (C). OC development was also studied using DCs that 
developed in dense cultures in the presence of glycolysis inhibitors (D). *p<0.05. 
In summary, we demonstrated that an increase in glycolytic activity that typically follows 
hypoxia, inflammation or tumor growth can downregulate the development of inflammatory 
DCs and increase DC-OC transdifferentiation. Previous studies have reported elevated lactate 
levels and decreased glucose concentrations in the SF of RA patients (229, 230), which might 
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be explained by the increased infiltration and activation of immune cells (231). Interestingly, 
an increased OC formation has been reported in hypoxia and the downregulation of HIF 
expression prevented experimental arthritis (231-234). Another important finding suggested a 
role for PAD enzymes in maintaining the functional plasticity iDCs to differentiate in to OCs 
and in the expression of citrullinated proteins. PAD enzyme expression is increased during 
hypoxia (235) and in inflammatory milieu (71). Our data indicated that lactic acid can 
reprogram DC development into an OC-prone pathway, which leads to increased PAD 
expression and protein citrullination, although the mechanistic link between glycolysis and 
protein citrullination remains to be understood (Paper III and IV). Protein citrullination might 
facilitate DC-OC transdifferentiation at steady state, and increase the targeting of the cells by 
ACPAs, which can potentially contribute to an accelerated bone erosion. 
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5 CONCLUSION AND FUTURE PERSPECTIVES 
In my thesis, I have focused on the molecular mechanisms underlying the effects of RA-
associated autoantibodies on bone erosion. Previous studies have indicated that ACPA 
positive individuals can develop bone loss and pain in the absence of inflammation (152, 
209). In our studies, we have established a link between adaptive immunity, i.e. 
autoantibodies, OC activation, bone destruction and pain.  
We demonstrated that certain ACPA clones can promote osteoclastogenesis through an IL-8-
mediated autocrine mechanism. ACPAs administered into mice could bind potential OC 
precursors in the bone marrow, induce local IL-8 production and pain triggered by IL-8 
binding to CXCR2 receptors in the nociceptors. Treatment with reparixin, an IL-8 antagonist, 
modulated ACPA-induced bone loss and pain-like behaviour in mice. These findings 
provided novel insights to the roles of ACPAs in bone destruction and pain, suggesting a 
novel pathogenic scenario and therapeutic opportunities for the early stages of RA 
development in ACPA-positive individuals.  
In the second part of the thesis (Paper I and IV), we have identified ACPA targets on the OC 
surface and we have found that protein citrullination by PAD enzymes is needed for both the 
steady state and the ACPA-mediated osteoclastogenesis. The expression of the citrullinated 
protein by OC precursors indicates that these cells can be targeted by ACPAs at the steady 
state, thus providing a potential explanation for ACPA-mediated bone loss in the absence of 
inflammation. Future studies are needed to address the exact contribution of PAD isozymes 
towards osteoclastogensis and the effects of PAD blocking in ACPA –dependent arthritis 
models. PAD inhibition or deficiency have been associated with decreased disease activity in 
collagen-induced or TNF-dependent arthritis models (81). PAD enzymes might therefore be 
important drug targets to prevent and treat both inflammation and ACPA-dependent bone loss 
in RA. 
In the last part of my thesis (Paper III and IV), we have focused on the heterogeneity of DCs 
and their functional plasticity to develop into OCs. We have proposed that the increase of 
glycolytic metabolism and protein citrullination, both are characteristic of the inflamed joints 
during RA, can turn the developing DCs towards OC differentiation, thereby contributing to 
increased bone damage.  
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Figure 16: ACPA induced osteoclastogensis leads to bone destruction and pain-like 
behavior. ACPAs can bind MФ and DC in the bone compartment and increase their 
differentiation into OC. IL-8 released during the differentiation process can activate the 
nociceptors and induce pain behaviour. 
Our future research aims to understand the intracellular mechanisms induced by ACPAs in 
developing OCs and we need to identify the key cell surface targets triggered by these 
autoantibodies. We would also like to understand how RA develops in ACPA-positive 
individuals through modelling ‘second hit’ mechanisms, through introducing transient joint 
inflammation in ACPA-injected mice. We anticipate that ACPA-dependent murine arthritis 
models, resembling human ACPA positive RA, will increase our overall knowledge in 
disease progression and provide opportunity for pre-clinical drug trials. Our hope is that in 
the near future be able to prevent bone loss and pain in ACPA positive at-risk individuals by 
modulating IL-8 and the PAD enzymes 
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